메뉴 건너뛰기
Journal of Virology
Volumn 88, Issue 3, 2014, Pages 1536-1547
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity
Author keywords

[No Author keywords available]
Indexed keywords

EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; RIBONUCLEASE H; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;
EID: 84892456974     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02904-13     Document Type: Article
Times cited : (16)
References (99)
  • 2
    • 0030923798 scopus 로고    scopus 로고
    • Impact of combination therapy for HIV infection on inpatient census
    • Torres RA, Barr M. 1997. Impact of combination therapy for HIV infection on inpatient census. N. Engl. J. Med. 336:1531-1532. http://dx.doi .org/10.1056/NEJM199705223362117.
    • (1997) N. Engl. J. Med. , vol.336 , pp. 1531-1532
    • Torres, R.A.1    Barr, M.2
  • 3
    • 0141793150 scopus 로고    scopus 로고
    • HIV resistance to nevirapine and other nonnucleoside reverse transcriptase inhibitors
    • Wainberg MA. 2003. HIV resistance to nevirapine and other nonnucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 34(Suppl 1):S2-S7.
    • (2003) J. Acquir. Immune Defic. Syndr. , vol.34 , Issue.SUPPL. 1
    • Wainberg, M.A.1
  • 4
    • 80051829496 scopus 로고    scopus 로고
    • Development of antiretroviral drug resistance
    • Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N. Engl. J. Med. 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
    • (2011) N. Engl. J. Med. , vol.365 , pp. 637-646
    • Wainberg, M.A.1    Zaharatos, G.J.2    Brenner, B.G.3
  • 5
    • 0024999452 scopus 로고
    • Retroviral reverse transcriptase: synthesis, structure, and function
    • Goff SP. 1990. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3:817-831.
    • (1990) J. Acquir. Immune Defic. Syndr. , vol.3 , pp. 817-831
    • Goff, S.P.1
  • 6
    • 0026693137 scopus 로고
    • Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
    • Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790. http://dx.doi.org/10.1126/science.1377403.
    • (1992) Science , vol.256 , pp. 1783-1790
    • Kohlstaedt, L.A.1    Wang, J.2    Friedman, J.M.3    Rice, P.A.4    Steitz, T.A.5
  • 8
    • 78649659732 scopus 로고    scopus 로고
    • The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine
    • Schuckmann MM, Marchand B, Hachiya A, Kodama EN, Kirby KA, Singh K, Sarafianos SG. 2010. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J. Biol. Chem. 285:38700-38709. http://dx.doi.org/10.1074/jbc.M110.153783.
    • (2010) J. Biol. Chem. , vol.285 , pp. 38700-38709
    • Schuckmann, M.M.1    Marchand, B.2    Hachiya, A.3    Kodama, E.N.4    Kirby, K.A.5    Singh, K.6    Sarafianos, S.G.7
  • 9
    • 84865099478 scopus 로고    scopus 로고
    • Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase
    • Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA. 2012. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J. Virol. 86:8422-8431. http://dx.doi.org/10.1128/JVI.00271-12.
    • (2012) J. Virol. , vol.86 , pp. 8422-8431
    • Xu, H.T.1    Oliveira, M.2    Quashie, P.K.3    McCallum, M.4    Han, Y.5    Quan, Y.6    Brenner, B.G.7    Wainberg, M.A.8
  • 10
    • 80051855982 scopus 로고    scopus 로고
    • Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase
    • Radzio J, Sluis-Cremer N. 2011. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase. Retrovirology 8:69. http://dx .doi.org/10.1186/1742-4690-8-69.
    • (2011) Retrovirology , vol.8 , pp. 69
    • Radzio, J.1    Sluis-Cremer, N.2
  • 12
    • 0033770149 scopus 로고    scopus 로고
    • Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)
    • Sluis-Cremer N, Arion D, Parniak MA. 2000. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell. Mol. Life Sci. 57:1408-1422. http://dx.doi.org/10.1007/PL00000626.
    • (2000) Cell. Mol. Life Sci. , vol.57 , pp. 1408-1422
    • Sluis-Cremer, N.1    Arion, D.2    Parniak, M.A.3
  • 13
    • 43049105858 scopus 로고    scopus 로고
    • Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase
    • Menendez-Arias L. 2008. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134:124-146. http://dx.doi.org/10.1016/j.virusres.2007.12.015.
    • (2008) Virus Res. , vol.134 , pp. 124-146
    • Menendez-Arias, L.1
  • 14
    • 84875010204 scopus 로고    scopus 로고
    • Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments
    • Menendez-Arias L. 2013. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 98:93-120. http://dx.doi.org/10.1016/j.antiviral.2013.01.007.
    • (2013) Antiviral Res. , vol.98 , pp. 93-120
    • Menendez-Arias, L.1
  • 15
    • 58149133507 scopus 로고    scopus 로고
    • Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition
    • Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713. http://dx.doi.org/10.1016/j.jmb.2008.10.071.
    • (2009) J. Mol. Biol. , vol.385 , pp. 693-713
    • Sarafianos, S.G.1    Marchand, B.2    Das, K.3    Himmel, D.M.4    Parniak, M.A.5    Hughes, S.H.6    Arnold, E.7
  • 16
    • 77955594846 scopus 로고    scopus 로고
    • Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase
    • Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG. 2010. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2:606-638. http://dx.doi.org/10.3390/v2020606.
    • (2010) Viruses , vol.2 , pp. 606-638
    • Singh, K.1    Marchand, B.2    Kirby, K.A.3    Michailidis, E.4    Sarafianos, S.G.5
  • 17
    • 43049144549 scopus 로고    scopus 로고
    • Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase
    • Ren J, Stammers DK. 2008. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 134:157-170. http://dx.doi.org/10.1016/j.virusres.2007.12.018.
    • (2008) Virus Res. , vol.134 , pp. 157-170
    • Ren, J.1    Stammers, D.K.2
  • 18
    • 43049148447 scopus 로고    scopus 로고
    • Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors
    • Sluis-Cremer N, Tachedjian G. 2008. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 134:147-156. http://dx.doi.org/10.1016/j.virusres.2008.01.002.
    • (2008) Virus Res. , vol.134 , pp. 147-156
    • Sluis-Cremer, N.1    Tachedjian, G.2
  • 20
    • 34547105526 scopus 로고    scopus 로고
    • Selection of mutations in the connection and RNaseHdomains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine
    • Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. 2007. Selection of mutations in the connection and RNaseHdomains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J. Virol. 81:7852-7859. http://dx.doi.org/10.1128/JVI.02203-06.
    • (2007) J. Virol. , vol.81 , pp. 7852-7859
    • Brehm, J.H.1    Koontz, D.2    Meteer, J.D.3    Pathak, V.4    Sluis-Cremer, N.5    Mellors, J.W.6
  • 21
    • 79952786073 scopus 로고    scopus 로고
    • Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations
    • Lengruber RB, Delviks-Frankenberry KA, Nikolenko GN, Baumann J, Santos AF, Pathak VK, Soares MA. 2011. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J. Antimicrob. Chemother. 66:702-708. http://dx.doi.org/10.1093/jac/dkr005.
    • (2011) J. Antimicrob. Chemother. , vol.66 , pp. 702-708
    • Lengruber, R.B.1    Delviks-Frankenberry, K.A.2    Nikolenko, G.N.3    Baumann, J.4    Santos, A.F.5    Pathak, V.K.6    Soares, M.A.7
  • 22
    • 41149145592 scopus 로고    scopus 로고
    • Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    • Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S. 2008. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 82:3261-3270. http://dx.doi.org/10.1128/JVI.01154-07.
    • (2008) J. Virol. , vol.82 , pp. 3261-3270
    • Hachiya, A.1    Kodama, E.N.2    Sarafianos, S.G.3    Schuckmann, M.M.4    Sakagami, Y.5    Matsuoka, M.6    Takiguchi, M.7    Gatanaga, H.8    Oka, S.9
  • 23
    • 64749091545 scopus 로고    scopus 로고
    • Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients
    • Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, Oka S. 2009. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res. 82:115-121. http://dx.doi .org/10.1016/j.antiviral.2009.02.189.
    • (2009) Antiviral Res. , vol.82 , pp. 115-121
    • Hachiya, A.1    Shimane, K.2    Sarafianos, S.G.3    Kodama, E.N.4    Sakagami, Y.5    Negishi, F.6    Koizumi, H.7    Gatanaga, H.8    Matsuoka, M.9    Takiguchi, M.10    Oka, S.11
  • 27
    • 77949362812 scopus 로고    scopus 로고
    • N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations
    • Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N. 2010. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. AIDS 24:659-667. http://dx.doi.org/10.1097/QAD.0b013e328336781d.
    • (2010) AIDS , vol.24 , pp. 659-667
    • Radzio, J.1    Yap, S.H.2    Tachedjian, G.3    Sluis-Cremer, N.4
  • 28
    • 84864944623 scopus 로고    scopus 로고
    • Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors
    • Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW. 2012. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin. Infect. Dis. 55:737-745. http://dx.doi.org/10.1093/cid/cis501.
    • (2012) Clin. Infect. Dis. , vol.55 , pp. 737-745
    • Brehm, J.H.1    Koontz, D.L.2    Wallis, C.L.3    Shutt, K.A.4    Sanne, I.5    Wood, R.6    McIntyre, J.A.7    Stevens, W.S.8    Sluis-Cremer, N.9    Mellors, J.W.10
  • 30
    • 77950652922 scopus 로고    scopus 로고
    • Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data
    • Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D. 2010. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir. Ther. 15:203-211. http://dx.doi.org/10.3851/IMP1511.
    • (2010) Antivir. Ther. , vol.15 , pp. 203-211
    • Price, H.1    Asboe, D.2    Pozniak, A.3    Gazzard, B.4    Fearnhill, E.5    Pillay, D.6    Dunn, D.7
  • 31
    • 2942560805 scopus 로고    scopus 로고
    • The impact of the M184V substitution on drug resistance and viral fitness
    • Wainberg MA. 2004. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti Infect. Ther. 2:147-151. http://dx.doi.org/10.1586/14787210.2.1.147.
    • (2004) Expert Rev. Anti Infect. Ther. , vol.2 , pp. 147-151
    • Wainberg, M.A.1
  • 32
    • 0344825778 scopus 로고    scopus 로고
    • Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1
    • Turner D, Brenner B, Wainberg MA. 2003. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin. Diagn. Lab. Immunol. 10:979-981. http://dx.doi.org/10.1128/CDLI.10.6.979-981.2003.
    • (2003) Clin. Diagn. Lab. Immunol. , vol.10 , pp. 979-981
    • Turner, D.1    Brenner, B.2    Wainberg, M.A.3
  • 33
    • 61449189645 scopus 로고    scopus 로고
    • Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
    • De Clercq E. 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33:307-320. http://dx.doi.org/10.1016/j.ijantimicag.2008.10.010.
    • (2009) Int. J. Antimicrob. Agents , vol.33 , pp. 307-320
    • De Clercq, E.1
  • 34
    • 84861977399 scopus 로고    scopus 로고
    • Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era
    • De Clercq E. 2012. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochem. Pharmacol. 84:241-248. http://dx.doi.org/10.1016/j.bcp.2012.03.024.
    • (2012) Biochem. Pharmacol. , vol.84 , pp. 241-248
    • De Clercq, E.1
  • 35
    • 84874114410 scopus 로고    scopus 로고
    • Antivirals: past, present and future
    • De Clercq E. 2013. Antivirals: past, present and future. Biochem. Pharmacol. 85:727-744. http://dx.doi.org/10.1016/j.bcp.2012.12.011.
    • (2013) Biochem. Pharmacol. , vol.85 , pp. 727-744
    • De Clercq, E.1
  • 36
    • 84888015201 scopus 로고    scopus 로고
    • 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE phase III trials
    • 28 May
    • Rimsky L, Van Eygen V, Hoogstoel A, Stevens M, Boven K, Picchio G, Vingerhoets J. 28 May 2013. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE phase III trials. Antivir. Ther. http://dx.doi.org/10.3851/IMP2636.
    • (2013) Antivir. Ther.
    • Rimsky, L.1    Van Eygen, V.2    Hoogstoel, A.3    Stevens, M.4    Boven, K.5    Picchio, G.6    Vingerhoets, J.7
  • 37
    • 78751693611 scopus 로고    scopus 로고
    • Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes
    • Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, Tremblay CL. 2011. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 55:600-607. http://dx.doi.org/10.1128/AAC.01192-10.
    • (2011) Antimicrob. Agents Chemother. , vol.55 , pp. 600-607
    • Asahchop, E.L.1    Oliveira, M.2    Wainberg, M.A.3    Brenner, B.G.4    Moisi, D.5    Toni, T.6    Tremblay, C.L.7
  • 38
    • 84876410269 scopus 로고    scopus 로고
    • Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline
    • Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. 2013. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 27:879-887. http://dx.doi.org/10 .1097/QAD.0b013e32835d9f6d.
    • (2013) AIDS , vol.27 , pp. 879-887
    • Asahchop, E.L.1    Wainberg, M.A.2    Oliveira, M.3    Xu, H.4    Brenner, B.G.5    Moisi, D.6    Ibanescu, I.R.7    Tremblay, C.8
  • 43
    • 80055103177 scopus 로고    scopus 로고
    • Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1
    • Hu Z, Kuritzkes DR. 2011. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J. Virol. 85:11309-11314. http://dx.doi.org/10.1128/JVI.05578-11.
    • (2011) J. Virol. , vol.85 , pp. 11309-11314
    • Hu, Z.1    Kuritzkes, D.R.2
  • 44
    • 80055119045 scopus 로고    scopus 로고
    • Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations
    • Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 85:11300-11308. http://dx.doi.org/10.1128/JVI.05584-11.
    • (2011) J. Virol. , vol.85 , pp. 11300-11308
    • Xu, H.T.1    Asahchop, E.L.2    Oliveira, M.3    Quashie, P.K.4    Quan, Y.5    Brenner, B.G.6    Wainberg, M.A.7
  • 47
    • 79960890917 scopus 로고    scopus 로고
    • How common is the nonnucleoside reverse transcriptase inhibitor mutation E138K in clinical practice?
    • Bradshaw D, Mandalia S, Nelson M. 2011. How common is the nonnucleoside reverse transcriptase inhibitor mutation E138K in clinical practice? J. Infect. 63:172-173. http://dx.doi.org/10.1016/j.jinf.2011.06 .003.
    • (2011) J. Infect. , vol.63 , pp. 172-173
    • Bradshaw, D.1    Mandalia, S.2    Nelson, M.3
  • 48
    • 84869234318 scopus 로고    scopus 로고
    • Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase
    • Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, Han Y, Quan Y, Wainberg MA. 2012. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase. J. Virol. 86:12983-12990. http://dx.doi.org/10.1128/JVI.02005-12.
    • (2012) J. Virol. , vol.86 , pp. 12983-12990
    • Xu, H.T.1    Oliveira, M.2    Asahchop, E.L.3    McCallum, M.4    Quashie, P.K.5    Han, Y.6    Quan, Y.7    Wainberg, M.A.8
  • 49
    • 84876149309 scopus 로고    scopus 로고
    • Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication
    • Zaharatos GJ, Wainberg MA. 2012. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Ann. Med. 45:236-241. http://dx.doi.org/10.3109/07853890.2012 .732704.
    • (2012) Ann. Med. , vol.45 , pp. 236-241
    • Zaharatos, G.J.1    Wainberg, M.A.2
  • 50
    • 84876913009 scopus 로고    scopus 로고
    • Rilpivirine/tenofovir/emtricitabine fixed-dose combination is an efficacious and well-tolerated "switch" regimen for patients on therapy
    • Ward D, Grant R. 2012. Rilpivirine/tenofovir/emtricitabine fixed-dose combination is an efficacious and well-tolerated "switch" regimen for patients on therapy. J. Int. AIDS Soc. 15:18351. http://dx.doi.org/10.7448/IAS.15.6.18351.
    • (2012) J. Int. AIDS Soc. , vol.15 , pp. 18351
    • Ward, D.1    Grant, R.2
  • 51
    • 84861419155 scopus 로고    scopus 로고
    • Rilpivirine and complera: new first-line treatment options
    • O'Neal R. 2011. Rilpivirine and complera: new first-line treatment options. BETA 23:14-18. http://www.sfaf.org/hiv-info/hot-topics/beta/beta-2011-fallwinter-drugwatch.pdf.
    • (2011) BETA , vol.23 , pp. 14-18
    • O'Neal, R.1
  • 52
    • 84865465384 scopus 로고    scopus 로고
    • Emtricitabine/rilpivirine/ tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection
    • Lyseng-Williamson KA, Scott LJ. 2012. Emtricitabine/rilpivirine/ tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Clin. Drug Invest. 32:715-722. http://dx.doi.org/10.1007/BF03261925.
    • (2012) Clin. Drug Invest. , vol.32 , pp. 715-722
    • Lyseng-Williamson, K.A.1    Scott, L.J.2
  • 53
    • 84873685857 scopus 로고    scopus 로고
    • Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
    • Wainberg MA. 2013. Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. HIV AIDS (Auckl.) 5:41-49. http://dx.doi.org/10.2147/HIV.S32377.
    • (2013) HIV AIDS (Auckl.) , vol.5 , pp. 41-49
    • Wainberg, M.A.1
  • 54
    • 0028176053 scopus 로고
    • Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/ template-switching reaction
    • Arts EJ, Li X, Gu Z, Kleiman L, Parniak MA, Wainberg MA. 1994. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/ template-switching reaction. J. Biol. Chem. 269:14672-14680.
    • (1994) J. Biol. Chem. , vol.269 , pp. 14672-14680
    • Arts, E.J.1    Li, X.2    Gu, Z.3    Kleiman, L.4    Parniak, M.A.5    Wainberg, M.A.6
  • 55
    • 77957377561 scopus 로고    scopus 로고
    • Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C
    • Xu HT, Quan Y, Asahchop E, Oliveira M, Moisi D, Wainberg MA. 2010. Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology 7:80. http://dx.doi.org/10.1186/1742-4690-7-80.
    • (2010) Retrovirology , vol.7 , pp. 80
    • Xu, H.T.1    Quan, Y.2    Asahchop, E.3    Oliveira, M.4    Moisi, D.5    Wainberg, M.A.6
  • 56
    • 0034469498 scopus 로고    scopus 로고
    • Relative replication fitness of a high-level 3'-azido-'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69
    • Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC. 2000. Relative replication fitness of a high-level 3'-azido-'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J. Virol. 74:10958-10964. http://dx.doi.org/10 .1128/JVI.74.23.10958-10964.2000.
    • (2000) J. Virol. , vol.74 , pp. 10958-10964
    • Imamichi, T.1    Berg, S.C.2    Imamichi, H.3    Lopez, J.C.4    Metcalf, J.A.5    Falloon, J.6    Lane, H.C.7
  • 57
    • 60349093648 scopus 로고    scopus 로고
    • Isolation of drug-resistant mutant HIV variants using tissue culture drug selection
    • Oliveira M, Brenner BG, Wainberg MA. 2009. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol. Biol. 485:427-433. http://dx.doi.org/10.1007/978-1-59745-170-3_29.
    • (2009) Methods Mol. Biol. , vol.485 , pp. 427-433
    • Oliveira, M.1    Brenner, B.G.2    Wainberg, M.A.3
  • 58
    • 0035984778 scopus 로고    scopus 로고
    • Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT
    • Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Wainberg MA. 2002. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 46:2087-2094. http://dx.doi.org/10.1128/AAC.46.7.2087-2094.2002.
    • (2002) Antimicrob. Agents Chemother. , vol.46 , pp. 2087-2094
    • Loemba, H.1    Brenner, B.2    Parniak, M.A.3    Ma'ayan, S.4    Spira, B.5    Moisi, D.6    Oliveira, M.7    Detorio, M.8    Wainberg, M.A.9
  • 59
    • 7244238110 scopus 로고    scopus 로고
    • Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture
    • Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG, Wainberg MA. 2004. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob. Agents Chemother. 48:4189-4194. http://dx.doi.org/10.1128/AAC.48.11.4189-4194.2004.
    • (2004) Antimicrob. Agents Chemother. , vol.48 , pp. 4189-4194
    • Petrella, M.1    Oliveira, M.2    Moisi, D.3    Detorio, M.4    Brenner, B.G.5    Wainberg, M.A.6
  • 60
    • 77952606637 scopus 로고    scopus 로고
    • The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity
    • Xu HT, Quan Y, Schader SM, Oliveira M, Bar-Magen T, Wainberg MA. 2010. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob. Agents Chemother. 54:2401-2408. http://dx.doi.org/10.1128/AAC.01795-09.
    • (2010) Antimicrob. Agents Chemother. , vol.54 , pp. 2401-2408
    • Xu, H.T.1    Quan, Y.2    Schader, S.M.3    Oliveira, M.4    Bar-Magen, T.5    Wainberg, M.A.6
  • 62
    • 0028789990 scopus 로고
    • Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase
    • Le Grice SF, Cameron CE, Benkovic SJ. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144. http://dx.doi.org/10.1016/0076-6879(95)62015-X.
    • (1995) Methods Enzymol. , vol.262 , pp. 130-144
    • Le Grice, S.F.1    Cameron, C.E.2    Benkovic, S.J.3
  • 63
    • 0025191211 scopus 로고
    • Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography
    • Le Grice SF, Gruninger-Leitch F. 1990. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187:307-314. http://dx.doi.org/10.1111/j.1432-1033.1990.tb15306.x.
    • (1990) Eur. J. Biochem. , vol.187 , pp. 307-314
    • Le Grice, S.F.1    Gruninger-Leitch, F.2
  • 64
    • 0141705300 scopus 로고    scopus 로고
    • Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C
    • Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, Wainberg MA. 2003. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res. Hum. Retroviruses 19:743-753. http://dx.doi.org/10 .1089/088922203769232548.
    • (2003) AIDS Res. Hum. Retroviruses , vol.19 , pp. 743-753
    • Quan, Y.1    Brenner, B.G.2    Marlink, R.G.3    Essex, M.4    Kurimura, T.5    Wainberg, M.A.6
  • 65
    • 0036971250 scopus 로고    scopus 로고
    • Fitness of drug resistant HIV-1: methodology and clinical implications
    • Quinones-Mateu ME, Arts EJ. 2002. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat. 5:224-233. http://dx.doi.org/10.1016/S1368-7646(02)00123-1.
    • (2002) Drug Resist Updat. , vol.5 , pp. 224-233
    • Quinones-Mateu, M.E.1    Arts, E.J.2
  • 66
    • 70350331091 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine
    • Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA. 2009. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob. Agents Chemother. 53:4667-4672. http://dx.doi.org/10.1128/AAC.00800-09.
    • (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 4667-4672
    • Xu, H.1    Quan, Y.2    Brenner, B.G.3    Bar-Magen, T.4    Oliveira, M.5    Schader, S.M.6    Wainberg, M.A.7
  • 67
    • 44049093742 scopus 로고    scopus 로고
    • Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect
    • Gao L, Hanson MN, Balakrishnan M, Boyer PL, Roques BP, Hughes SH, Kim B, Bambara RA. 2008. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J. Biol. Chem. 283:9196-9205. http://dx.doi.org/10.1074/jbc.M710148200.
    • (2008) J. Biol. Chem. , vol.283 , pp. 9196-9205
    • Gao, L.1    Hanson, M.N.2    Balakrishnan, M.3    Boyer, P.L.4    Roques, B.P.5    Hughes, S.H.6    Kim, B.7    Bambara, R.A.8
  • 68
    • 0029968985 scopus 로고    scopus 로고
    • Strand displacement synthesis in the central polypurine tract region of HIV-1 promotes DNA to DNA strand transfer recombination
    • Fuentes GM, Palaniappan C, Fay PJ, Bambara RA. 1996. Strand displacement synthesis in the central polypurine tract region of HIV-1 promotes DNA to DNA strand transfer recombination. J. Biol. Chem. 271: 29605-29611. http://dx.doi.org/10.1074/jbc.271.47.29605.
    • (1996) J. Biol. Chem. , vol.271 , pp. 29605-29611
    • Fuentes, G.M.1    Palaniappan, C.2    Fay, P.J.3    Bambara, R.A.4
  • 69
    • 0032993043 scopus 로고    scopus 로고
    • The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end-and DNA 3'-end-directed RNase H activities
    • Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM. 1999. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end-and DNA 3'-end-directed RNase H activities. J. Virol. 73:5803-5813.
    • (1999) J. Virol. , vol.73 , pp. 5803-5813
    • Gerondelis, P.1    Archer, R.H.2    Palaniappan, C.3    Reichman, R.C.4    Fay, P.J.5    Bambara, R.A.6    Demeter, L.M.7
  • 70
    • 0030966369 scopus 로고    scopus 로고
    • Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNaseHfunction
    • Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, Bambara RA. 1997. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNaseHfunction. J. Biol. Chem. 272:11157-11164. http://dx.doi.org/10.1074/jbc.272.17.11157.
    • (1997) J. Biol. Chem. , vol.272 , pp. 11157-11164
    • Palaniappan, C.1    Wisniewski, M.2    Jacques, P.S.3    Le Grice, S.F.4    Fay, P.J.5    Bambara, R.A.6
  • 71
    • 0033863784 scopus 로고    scopus 로고
    • Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
    • Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401. http://dx.doi.org/10.1128/JVI.74.18.8390-8401.2000.
    • (2000) J. Virol. , vol.74 , pp. 8390-8401
    • Archer, R.H.1    Dykes, C.2    Gerondelis, P.3    Lloyd, A.4    Fay, P.5    Reichman, R.C.6    Bambara, R.A.7    Demeter, L.M.8
  • 72
    • 0035799358 scopus 로고    scopus 로고
    • The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNaseHcleavages
    • Archer RH, Wisniewski M, Bambara RA, Demeter LM. 2001. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNaseHcleavages. Biochemistry 40:4087-4095. http://dx.doi.org/10.1021/bi002328a.
    • (2001) Biochemistry , vol.40 , pp. 4087-4095
    • Archer, R.H.1    Wisniewski, M.2    Bambara, R.A.3    Demeter, L.M.4
  • 73
    • 0029745634 scopus 로고    scopus 로고
    • A drug resistance mutation in the inhibitor binding pocket ofhumanimmunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation
    • Fan N, Rank KB, Slade DE, Poppe SM, Evans DB, Kopta LA, Olmsted RA, Thomas RC, Tarpley WG, Sharma SK. 1996. A drug resistance mutation in the inhibitor binding pocket ofhumanimmunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry 35: 9737-9745. http://dx.doi.org/10.1021/bi9600308.
    • (1996) Biochemistry , vol.35 , pp. 9737-9745
    • Fan, N.1    Rank, K.B.2    Slade, D.E.3    Poppe, S.M.4    Evans, D.B.5    Kopta, L.A.6    Olmsted, R.A.7    Thomas, R.C.8    Tarpley, W.G.9    Sharma, S.K.10
  • 74
    • 41249088246 scopus 로고    scopus 로고
    • Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability
    • Figueiredo A, Zelina S, Sluis-Cremer N, Tachedjian G. 2008. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Curr. HIV Res. 6:130-137. http://dx.doi.org/10.2174/157016208783885065.
    • (2008) Curr. HIV Res. , vol.6 , pp. 130-137
    • Figueiredo, A.1    Zelina, S.2    Sluis-Cremer, N.3    Tachedjian, G.4
  • 75
    • 33646237789 scopus 로고    scopus 로고
    • The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys,3) that correlate with reductions in replication efficiency
    • Wang J, Dykes C, Domaoal RA, Koval CE, Bambara RA, Demeter LM. 2006. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys,3) that correlate with reductions in replication efficiency. Virology 348:462-474. http://dx.doi.org/10.1016/j.virol.2006.01.014.
    • (2006) Virology , vol.348 , pp. 462-474
    • Wang, J.1    Dykes, C.2    Domaoal, R.A.3    Koval, C.E.4    Bambara, R.A.5    Demeter, L.M.6
  • 77
    • 77951456442 scopus 로고    scopus 로고
    • A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    • Nikolenko GN, Delviks-Frankenberry KA, Pathak VK. 2010. A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 84:5238-5249. http://dx.doi.org/10.1128/JVI.01545-09.
    • (2010) J. Virol. , vol.84 , pp. 5238-5249
    • Nikolenko, G.N.1    Delviks-Frankenberry, K.A.2    Pathak, V.K.3
  • 79
    • 0030004944 scopus 로고    scopus 로고
    • Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
    • Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
    • (1996) J. Virol. , vol.70 , pp. 2146-2153
    • Caliendo, A.M.1    Savara, A.2    An, D.3    DeVore, K.4    Kaplan, J.C.5    D'Aquila, R.T.6
  • 80
    • 0034947293 scopus 로고    scopus 로고
    • Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chainterminator removal and viral replication
    • Naeger LK, Margot NA, Miller MD. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chainterminator removal and viral replication. Antivir. Ther. 6:115-126. http://www.intmedpress.com/serveFile.cfm?sUID=2ff8a47f-5dab-4334-801d-22555a8ac458.
    • (2001) Antivir. Ther. , vol.6 , pp. 115-126
    • Naeger, L.K.1    Margot, N.A.2    Miller, M.D.3
  • 81
    • 0032875344 scopus 로고    scopus 로고
    • Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val
    • Sharma PL, Crumpacker CS. 1999. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J. Virol. 73:8448-8456.
    • (1999) J. Virol. , vol.73 , pp. 8448-8456
    • Sharma, P.L.1    Crumpacker, C.S.2
  • 82
    • 0030691001 scopus 로고    scopus 로고
    • Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
    • Back NK, Berkhout B. 1997. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 41:2484-2491.
    • (1997) Antimicrob. Agents Chemother. , vol.41 , pp. 2484-2491
    • Back, N.K.1    Berkhout, B.2
  • 83
    • 82955198409 scopus 로고    scopus 로고
    • Drug resistance in HIV-1
    • Kuritzkes DR. 2011. Drug resistance in HIV-1. Curr. Opin. Virol. 1:582-589. http://dx.doi.org/10.1016/j.coviro.2011.10.020.
    • (2011) Curr. Opin. Virol. , vol.1 , pp. 582-589
    • Kuritzkes, D.R.1
  • 86
    • 84859920508 scopus 로고    scopus 로고
    • Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection
    • Croxtall JD. 2012. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs 72:847-869. http://dx.doi.org/10.2165/11209110-000000000-00000.
    • (2012) Drugs , vol.72 , pp. 847-869
    • Croxtall, J.D.1
  • 87
    • 83655163698 scopus 로고    scopus 로고
    • Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis
    • Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G. 2012. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J. Acquir. Immune Defic. Syndr. 59:39-46. http://dx.doi.org/10.1097/QAI.0b013e31823df4da.
    • (2012) J. Acquir. Immune Defic. Syndr. , vol.59 , pp. 39-46
    • Rimsky, L.1    Vingerhoets, J.2    Van Eygen, V.3    Eron, J.4    Clotet, B.5    Hoogstoel, A.6    Boven, K.7    Picchio, G.8
  • 88
    • 40349091258 scopus 로고    scopus 로고
    • High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations
    • Das K, Bauman JD, Clark AD, Jr, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E. 2008. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U.S.A. 105:1466-1471. http://dx.doi.org/10.1073/pnas.0711209105.
    • (2008) Proc. Natl. Acad. Sci. U.S.A. , vol.105 , pp. 1466-1471
    • Das, K.1    Bauman, J.D.2    Clark Jr., A.D.3    Frenkel, Y.V.4    Lewi, P.J.5    Shatkin, A.J.6    Hughes, S.H.7    Arnold, E.8
  • 89
    • 77952724079 scopus 로고    scopus 로고
    • Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design
    • Lansdon EB, Brendza KM, Hung M, Wang R, Mukund S, Jin D, Birkus G, Kutty N, Liu X. 2010. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem. 53:4295-4299. http://dx.doi.org/10.1021/jm1002233.
    • (2010) J. Med. Chem. , vol.53 , pp. 4295-4299
    • Lansdon, E.B.1    Brendza, K.M.2    Hung, M.3    Wang, R.4    Mukund, S.5    Jin, D.6    Birkus, G.7    Kutty, N.8    Liu, X.9
  • 90
    • 77649254869 scopus 로고    scopus 로고
    • Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies
    • Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Bethune MP, De Smedt G, Woodfall B, Picchio G. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24:503-514. http://dx.doi.org/10.1097/QAD.0b013e32833677ac.
    • (2010) AIDS , vol.24 , pp. 503-514
    • Vingerhoets, J.1    Tambuyzer, L.2    Azijn, H.3    Hoogstoel, A.4    Nijs, S.5    Peeters, M.6    de Bethune, M.P.7    De Smedt, G.8    Woodfall, B.9    Picchio, G.10
  • 91
    • 26444595584 scopus 로고    scopus 로고
    • TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments
    • Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Bethune MP. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782. http://dx.doi.org/10 .1128/JVI.79.20.12773-12782.2005.
    • (2005) J. Virol. , vol.79 , pp. 12773-12782
    • Vingerhoets, J.1    Azijn, H.2    Fransen, E.3    De Baere, I.4    Smeulders, L.5    Jochmans, D.6    Andries, K.7    Pauwels, R.8    de Bethune, M.P.9
  • 92
    • 80055110312 scopus 로고    scopus 로고
    • Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine
    • Tambuyzer L, Nijs S, Daems B, Picchio G, Vingerhoets J. 2011. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J. Acquir. Immune Defic. Syndr. 58:18-22. http://dx.doi.org/10.1097/QAI .0b013e3182237f74.
    • (2011) J. Acquir. Immune Defic. Syndr. , vol.58 , pp. 18-22
    • Tambuyzer, L.1    Nijs, S.2    Daems, B.3    Picchio, G.4    Vingerhoets, J.5
  • 93
    • 0037974512 scopus 로고    scopus 로고
    • The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
    • Diallo K, Brenner B, Oliveira M, Moisi D, Detorio M, Gotte M, Wainberg MA. 2003. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob. Agents Chemother. 47:2376-2379. http://dx.doi.org/10.1128/AAC.47.7.2376-2379 .2003.
    • (2003) Antimicrob. Agents Chemother. , vol.47 , pp. 2376-2379
    • Diallo, K.1    Brenner, B.2    Oliveira, M.3    Moisi, D.4    Detorio, M.5    Gotte, M.6    Wainberg, M.A.7
  • 95
    • 0037131303 scopus 로고    scopus 로고
    • Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates
    • Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ. 2002. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 16:F41-F47. http://dx.doi .org/10.1097/00002030-200210180-00002.
    • (2002) AIDS , vol.16
    • Whitcomb, J.M.1    Huang, W.2    Limoli, K.3    Paxinos, E.4    Wrin, T.5    Skowron, G.6    Deeks, S.G.7    Bates, M.8    Hellmann, N.S.9    Petropoulos, C.J.10
  • 96
    • 84879012959 scopus 로고    scopus 로고
    • Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine
    • Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA. 2013. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrob. Agents Chemother. 57:3100-3109. http://dx.doi.org/10.1128/AAC .00348-13.
    • (2013) Antimicrob. Agents Chemother. , vol.57 , pp. 3100-3109
    • Xu, H.T.1    Colby-Germinario, S.P.2    Asahchop, E.L.3    Oliveira, M.4    McCallum, M.5    Schader, S.M.6    Han, Y.7    Quan, Y.8    Sarafianos, S.G.9    Wainberg, M.A.10
  • 98
    • 74249098867 scopus 로고    scopus 로고
    • N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations
    • Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G. 2010. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. AIDS 24: 317-319. http://dx.doi.org/10.1097/QAD.0b013e3283315697.
    • (2010) AIDS , vol.24 , pp. 317-319
    • Sluis-Cremer, N.1    Moore, K.2    Radzio, J.3    Sonza, S.4    Tachedjian, G.5
  • 99
    • 77956257799 scopus 로고    scopus 로고
    • N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation
    • Biondi MJ, Beilhartz GL, McCormick S, Gotte M. 2010. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation. J. Biol. Chem. 285: 26966-26975. http://dx.doi.org/10.1074/jbc.M110.105775.
    • (2010) J. Biol. Chem. , vol.285 , pp. 26966-26975
    • Biondi, M.J.1    Beilhartz, G.L.2    McCormick, S.3    Gotte, M.4

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.